SHR-A1811 Injection for uterine cervical neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Jul 2025: Trial registered, NCT07051486
  2. 11 Oct 2025: Trial started, NCT07051486

The trials

NCT07051486: A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

State
Under way
Phase
Phase 2
People
60 planned
Started
11 Oct 2025
Primary completion
Feb 2026
Arms
SHR-A1811 Group
Results
None posted
  1. 4 Jul 2025: Trial registered
  2. 11 Oct 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.